How should epigastric pain syndrome (EPS) without esophagitis be treated?

Treatment of Epigastric Pain Syndrome (EPS) Without Esophagitis

For epigastric pain syndrome without esophagitis, initiate a 4-8 week trial of once-daily proton pump inhibitor (PPI) therapy, escalating to twice-daily dosing if symptoms persist, then taper to the lowest effective dose once symptoms are controlled. 1

Initial Management Approach

Start with patient education and lifestyle modifications tailored to individual triggers. Avoid broadly enforcing all lifestyle changes—instead, target specific modifications based on the patient's history. If overweight, recommend weight loss. If symptoms consistently follow alcohol, coffee, or spicy foods, advise avoidance of these specific triggers. 2

Pharmacologic Treatment Algorithm

First-Line Therapy

• Begin with once-daily PPI for 4-8 weeks in patients with troublesome epigastric pain without alarm symptoms 1
• PPIs are more effective than H2-receptor antagonists (H2RAs), which are more effective than placebo for symptomatic esophageal syndromes without esophagitis (Grade B recommendation) 2
• Emphasize to patients that PPIs are safe for GERD-spectrum disorders 1

Escalation Strategy

If inadequate response after 4-8 weeks:

• Increase to twice-daily PPI dosing (e.g., omeprazole 20 mg twice daily or equivalent) 1
• Alternative: Switch to a more potent acid suppressive agent once daily 1
• Patients failing twice-daily PPI therapy should be considered treatment failures—this is the reasonable upper limit for empirical therapy 2

De-escalation After Response

When symptoms adequately respond:

• Taper PPI to the lowest effective dose that controls symptoms 1
• Consider on-demand therapy with H2-blockers or antacids for breakthrough symptoms 1
• If PPI therapy continues beyond 12 months without objective GERD confirmation, evaluate appropriateness and consider endoscopy with prolonged wireless pH monitoring off PPI 1

Critical Diagnostic Considerations

When to Pursue Objective Testing

Perform upfront endoscopy (rather than empirical PPI trial) if: 1, 2

• Alarm symptoms are present
• Symptoms fail to respond adequately to PPI trial
• Long-term PPI therapy is planned without proven GERD

If endoscopy shows no erosive disease (Los Angeles B or greater) or Barrett's esophagus:

• Perform prolonged wireless pH monitoring off medication (96-hour preferred) to confirm or rule out GERD 1, 2, 1

Important Nuance: EPS vs. GERD Overlap

Recent evidence suggests that EPS frequently overlaps with GERD rather than being purely a functional disorder 3. Approximately 40% of EPS patients have postprandial epigastric pain, blurring the distinction from postprandial distress syndrome 4. This supports the rationale for PPI trials in EPS, as these patients may have underlying acid-related pathology.

Adjunctive and Alternative Therapies

If PPI Therapy Fails

Consider personalized adjunctive pharmacotherapy based on symptom phenotype: 1

• Alginate antacids for breakthrough symptoms
• Nighttime H2RAs for nocturnal symptoms
• Baclofen for regurgitation or belch-predominant symptoms

Neuromodulation

For patients with functional heartburn or reflux hypersensitivity (confirmed by normal pH monitoring):

• Tricyclic antidepressants (TCAs) as neuromodulators 5, 6
• Referral for cognitive behavioral therapy, hypnotherapy, or diaphragmatic breathing 1, 7
• PPI can be discontinued or tapered in these patients 1

Common Pitfalls to Avoid

1. Do NOT use metoclopramide as monotherapy or adjunctive therapy—it is specifically recommended against (Grade D) 2

2. Do NOT add nocturnal H2RA to twice-daily PPI—there is no evidence of improved efficacy with this combination 2

3. Do NOT continue empirical PPI indefinitely without objective testing—if long-term therapy is needed, confirm GERD diagnosis with endoscopy and pH monitoring 1

4. Do NOT assume all epigastric pain is meal-unrelated—newer data shows significant overlap between EPS and postprandial symptoms, requiring individualized assessment 4

5. Avoid opioids—they should never be prescribed for chronic gastrointestinal pain from disorders of gut-brain interaction 5

Shared Decision-Making

Develop a care plan with the patient that includes: 1

• Investigation strategy for symptoms
• Explanation of potential risks and benefits of therapy
• Long-term management plan including possible de-escalation
• Clear communication about why PPIs are prescribed (for EPS, not just "reflux")